Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis

PharmacoEconomics

Volumn 13, Issue 2, 1998, Pages 243-256

  Gupta, Aditya K ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATOPHYTE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; MALAISE; META ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PHARMACOECONOMICS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; TOE; UNITED STATES; URTICARIA; VASCULITIS; VERTIGO;

ANTIFUNGAL AGENTS; COSTS AND COST ANALYSIS; FOOT DERMATOSES; GRISEOFULVIN; HUMANS; ITRACONAZOLE; NAPHTHALENES; ONYCHOMYCOSIS; UNITED STATES;

EID: 0031891873     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813020-00007     Document Type: Article

References (92)

1. Gupta AK, Jain HC, Lynde CW, et al. Prevalence of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada: a multicenter study of 2001 patients. Int J Dermatol 1997; 36: 783-7
2. Charif M, Elewski BE. The prevalence of onychomycosis in Northeastern Ohio. Arch Dermatol 1997; 133: 1172-3
3. Pardo-Costello V, Pardo OA. Diseases of the nails. Springfield (IL): Charles C Thomas, 1960
4. Achten G, Wanet-Rouard J. Onychomycoses in the laboratory. Mykosen 1978; 21: 125-7
5. Grigoriu D, Grigoriu A. Les onychomycoses. Rev Med Suisse Romande 1975; 95: 839-49
6. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
7. Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis. Dermatol Clin 1997; 15 (1): 121-35
8. De Doncker P, Decroix J, Pierard GE, et al. Itraconazole pulse therapy is effective in the treatment of onychomycosis: a pharmacokinetic/ pharmacodynamic and clinical evaluation. Arch Dermatol 1996; 132: 34-41
9. Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757-77
10. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35-44
11. Van Doorslaer EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239-44
12. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-8
13. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1 1991; 35: 192-5
14. BeDell LS, editor. Mosby's complete drug reference. Physicians Gen Rx. ed. St. Louis: Mosby-Year Book Inc., 1997
15. Health Care Finance Administration. 1995 Annual Medicare Physician Fee Schedule-Carrier File. Baltimore: Empire New York Carrier, 1995
16. Health Care Finance Administration. 1995 Clinical Diagnostic Lab Fee Schedule-Carrier File. Baltimore: Empire New York Carrier, 1995
17. Janssen Pharmaceutica Inc. Itraconazole product monograph. Titusville (NJ): Janssen Pharmaceutica Inc., 1996
18. Sandoz Pharmaceuticals Corporation Inc. Terbinafine product monograph. East Hanover (NJ): Sandoz Pharmaceuticals Corporation Inc., 1996
19. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3
20. Montero-Gei M, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35: 587-8
21. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126: 61-9
22. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis: an overview. Int J Dermatol. In press
23. Scher RK. A placebo-controlled, randomized, double-blind trial of once weekly fluconazole (150, 300 or 140mg) in the treatment of distal subungual onychomycosis of the toenail. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sep 28-Oct 1; Toronto
24. Einarson TR, Arikian SR, Doyle JJ. Rank-order stability analysis (ROSA): testing pharmacoeconomic data. Med Decis Making 1995; 15: 367-72
25. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ 1967; 3: 464-9
26. Russell B, Frain-Bell W, Riddell RW, et al. Chronic ringworm infection of the skin and nails treated with griseofulvin. Lancet 1960; 1: 1140-7
27. Svejgaard E. Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Derm Venereol (Stockh) 1985; 65: 143-9
28. Korting HC, Schafer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37: 2064-8
29. Walsøe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: Open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137-40
30. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent, Int J Dermatol 1991; 30: 586-9
31. Hofmann H, Bräutigam M, Weidinger G, et al. Treatment of toenail onychomycosis: A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-22
32. Goldfarb NJ, Sulzberger MB. Experiences in one hundred thirty-seven patients with oral griseofulvin. Arch Dermatol 1960; 81: 859-62
33. Kaminsky A. Comparative effects of griseofulvin on onychomycosis and on psoriasis. Arch Dermatol 1960; 60 (5): 838-40
34. Williams DI. Griseofulvin and Trichophyton rubrum infections. Arch Dermatol 1960; 81: 769-71
35. Hay RJ, Clayton YM, Griffiths WAD, et al. A comparative double-blind study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol 1985; 112: 691-6
36. Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother 1992; 29: 195-205
37. Stevenson CJ, Djavahiszwili N. Chronic ringworm of the nails. Lancet 1961; 1: 373-4
38. Levin H, Alden HS, Ajello L. Use of griseofulvin in office practice. Arch Dermatol 1960; 81(5): 827-32
39. Quintaville P. Onychomycosis treated with ultrafine griseofulvin. J Am Podiat Assoc 1966; 56: 119-20
40. Dillaha CJ, Jansen GT. Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. Arch Dermatol 1960; 81: 192-198
41. Blank H, Smith GJ, Roth FJ, et al. Griseofulvin for the systemic treatment of dermatomycoses. JAMA 1959; 171: 2168-74
42. Maibach HI, Kligman AM. Short-term treatment of onychomycosis with griseofulvin. Arch Dermatol 1960; 18: 733-4
43. González-Ochoa A, Ahumada-Padilla M. New schemes in the treatment of dermatophytoses with griseofulvin. Arch Dermatol 1960; 81 (5): 833-7
44. Haneke E, Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-7
45. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-5
46. Haneke E, Delescluse J, Plinck EPB, et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6: 7-10
47. De Backer M, De Keyser P, De Vroey C, et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250mg/day vs. itraconazole 200mg/day-a double-blind comparative trial. Br J Dermatol 1996; 134 Suppl. 46: 16-7
48. Bräutigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995; 311: 919-22
49. Arenas R, Dominguez-Cherit J, Ferńndez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1993; 34: 138-43
50. Odom R, Daniel R, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996; 35 (1): 110-1
51. Jones HE, Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail, Int J Dermatol 1996; 35 (8): 589-90
52. Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-4
53. André J, De Doncker P, Laporte M, et al. Onychomycosis caused by Microsporum canis: treatment with itraconazole. J Am Acad Dermatol 1995; 32: 1052-3
54. Hanifin JM, Tofte SJ. Itraconazole therapy for recalcitrant dermatophyte infections. J Am Acad Dermatol 1988; 18: 1077-80
55. Rongioletti F, Robert E, Tripodi S, et al. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992; 2: 145-6
56. Stary A, Storch M, Hörting-Müller I. Systemic treatment of onychomycosis with itraconazole: clinical and mycological results [abstract]. 3rd Congress of the European Academy of Dermatology and Venereology; 1993 Sep 26-30: Copenhagen, 348
57. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-66
58. DePadova-Elder SM, Ditre CM, Kantor GR, et al. Candidiasis endocrinopathy syndrome. Arch Dermatol 1994; 130: 19-22
59. Kim JA, Ahn KJ, Kim JM, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56: 1066-75
60. De Doncker PRG, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173-7
61. Hay RJ, Baran R, Moore MK, et al. Candida onychomycosis: an evaluation of the role of Candida species in nail disease. Br J Dermatol 1988; 118: 47-58
62. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-3
63. Itraconazole product monograph. Ontario: Jannsen-Ortho, 1997
64. Bonifaz A, Carrasco-Gerard E, Saúl A. Itraconazole in onychomycosis: Intermittent dose schedule. Int J Dermatol 1997; 36: 70-2
65. Hancke E, Ring J, Tajerbashi D, et al. Efficacy and safety of itraconazole 1-week pulse therapy in the treatment of onychomycosis: an open German multicenter trial [poster presentation]. 54th Annual Meeting of the American Academy of Dermatology; 1996 Feb 10-15; Washington, DC
66. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600
67. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304: 1151-4
68. Van Der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126: 36-9
69. Galimberti R, Kowalczuk A, Flores V, et al. Onychomycosis treated with a short course of oral terbinafine. Int J Dermatol 1996; 35 (5): 374-5
70. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33 (5 Pt 1): 775-9
71. Svejgaard EL, Brandrup F, Dragballe K, et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh) 1997; 77: 66-9
72. Rakosi T. Terbinafine and onychomycosis [abstract]. Dermatologica 1990; 181: 174
73. Shuster S, Munro C. Single dose treatment of fungal nail disease [letter]. Lancet 1992; 339: 1066
74. Zaias N. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol 1990; 23: 810-2
75. Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126: 40-6
76. Goodfield MJD, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121: 753-7
77. Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126: 33-5
78. Goodfield MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treat 1990; 1: 55-7
79. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-3
80. Savin RC, Atton AV. Terbinafine in onychomycosis: a mini study. Int J Dermatol 1993; 32: 918-9
81. Eastcott DF. Terbinafine and onychomycosis [letter]. N Z Med J 1991; 104: 17
82. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995; 133: 329-47
83. Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130: 16-21
84. Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35 (6): 958-61
85. Roberts DT, Richardson MD. Dwyer PK, et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 3: 39-42
86. Tosti A, Piraccini BM, Stinchi C, et al. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996; 135: 799-802
87. Lee KH, Kim YS, Kim MS, et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996; 28: 1488-9
88. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130: 32-4
89. Halpern MT, Palmer C. Modeling the cost-effectiveness of oral therapy for nail fungus. Am J Man Care 1996; 2: 59-66
90. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989; 32: 609-19
91. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Dermatol 1986; 18: 263-8
92. Griseofulvin® Product Information, Physician's Desk Reference. Montvale (NJ): Medical Economics Company, Inc., 1997: 2499-501